Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma

被引：0
|
作者：
Emilio Bajetta
机构：
[1] E Bajetta is Chief of Medical Oncology,
[2] IRCCS Fondazione 'Istituto Nazionale dei Tumori',undefined
[3] Milan,undefined
[4] Italy.,undefined
来源：
Nature Clinical Practice Oncology | 2008年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The incidence of the skin malignancy, melanoma, is increasing and it often becomes refractory to common therapies after metastasis. In this Viewpoint the author discusses different therapeutic approaches for metastatic melanoma.
引用
收藏
页码：4 / 5
页数：1
相关论文
共 50 条
  • [1] Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma
    Bajetta, Emilio
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 4 - 5
  • [2] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    Panelli, Monica C.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 2 - 3
  • [3] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Ahmad A Tarhini
    Stergios J Moschos
    Monica C Panelli
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 2 - 3
  • [4] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Eggermont, Alexander M. M.
    Bouwhuis, Marna G.
    Kruit, Wim H.
    Testori, Alessandro
    ten Hagen, Timo
    Yver, Antoine
    Xu, Christine
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 671 - 677
  • [5] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Alexander M. M. Eggermont
    Marna G. Bouwhuis
    Wim H. Kruit
    Alessandro Testori
    Timo ten Hagen
    Antoine Yver
    Christine Xu
    [J]. Cancer Chemotherapy and Pharmacology, 2010, 65 : 671 - 677
  • [6] Adjuvant pegylated interferon α-2b therapy for melanoma
    Schilling, Bastian
    Vaubel, Julia
    Schadendorf, Dirk
    [J]. ONCOLOGY LETTERS, 2010, 1 (02) : 237 - 241
  • [7] Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
    Eggermont, AMM
    Suciu, S
    MacKie, R
    Ruka, W
    Testori, A
    Kruit, W
    Punt, CJA
    Delauney, M
    Sales, F
    Groenewegen, G
    Ruiter, DJ
    Jagiello, I
    Stoitchkov, K
    Keilholz, U
    Lienard, D
    [J]. LANCET, 2005, 366 (9492): : 1189 - 1196
  • [8] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
    Tao Li
    Dong-Dong Jia
    Li-Song Teng
    [J]. Investigational New Drugs, 2020, 38 : 1334 - 1341
  • [9] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
    Li, Tao
    Jia, Dong-Dong
    Teng, Li-Song
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1334 - 1341
  • [10] Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation
    Bouwhuis, M. G.
    Suciu, S.
    Testori, A.
    Santinami, M.
    Kruit, W. H.
    Punt, C. J.
    Sales, F.
    Patel, P. M.
    Spatz, A.
    Eggermont, A. M. M.
    [J]. EJC SUPPLEMENTS, 2007, 5 (06): : 5 - 6
12345